Mosaic Immunoengineering INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
Mosaic ImmunoEngineering and Oncotelic Therapeutics have extended the deadline for their potential acquisition agreement to June 30, 2025, to allow more time for due diligence and finalizing the deal.
OTC.Pink
Carlton Johnson has resigned from the Board of Directors of Mosaic ImmunoEngineering, Inc., effective immediately, also stepping down from all board committees.
OTC.Pink
Mosaic ImmunoEngineering's CFO, Paul Lytle, will transition to a part-time role effective June 1, 2024, as the company seeks a $4 million capital raise.
OTC.Pink
Mosaic ImmunoEngineering has changed its independent registered public accounting firm from KMJ Corbin & Company LLP to Rose, Snyder & Jacobs LLP, effective May 22, 2024.
OTC.Pink
8-K: Mosaic ImmunoEngineering to Acquire Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics
Mosaic ImmunoEngineering has agreed to acquire clinical-stage necroptosis cancer therapy assets and AI technology from Oncotelic Therapeutics in a deal involving stock and potential milestone payments.
OTC.Pink
Mosaic ImmunoEngineering reports the passing of independent director Gloria Felcyn, who served on the board since 2002.
OTC.Pink
Mosaic ImmunoEngineering has had its exclusive license agreement with Case Western Reserve University terminated due to financial default, jeopardizing its lead immunotherapy candidate.